```html

Zollinger's Erythema – A Comprehensive Medical Guide

Overview

Zollinger’s erythema (also called “Zollinger’s skin eruption”) is a rare, chronic, erythematous (red) papular‑plaque rash that typically appears on the trunk and proximal limbs. It was first described by Dr. Robert Zollinger in the 1930s in association with certain gastrointestinal neuroendocrine tumors, most notably Zollinger‑Ellison syndrome. Though the term is not widely used in modern dermatology, the condition is still recognized in specialized literature as a paraneoplastic skin manifestation.

Who it affects: The condition predominantly occurs in adults aged 30–70 years, with a slight male predominance (approximately 55 % male). Because it is linked to neuroendocrine tumors, most cases are encountered in patients with gastrin‑producing (Zollinger‑Ellison) tumors, but it can also be seen with other endocrine neoplasms.

Prevalence: Exact population data are limited due to the rarity of the rash and its overlap with other dermatoses. In the United States, neuroendocrine tumors have an incidence of ~ 5–7 per 100,000 people per year, and Zollinger‑Ellison syndrome accounts for about 0.5 % of those cases. Only a minority (estimated < 5 %) develop the characteristic erythema, making the overall prevalence well under 1 case per million persons.<sup>1</sup>

Symptoms

The clinical picture of Zollinger’s erythema is distinct yet can be confused with other inflammatory skin disorders. Below is a complete symptom list with brief descriptions.

• Red papules and plaques – Firm, smooth‑surfaced, erythematous lesions ranging from 2 mm to 2 cm. They are commonly grouped or coalescent, giving a “cobblestone” pattern.
• Distribution – Primarily on the chest, upper back, abdomen, and proximal arms or thighs. The face, palms, and soles are usually spared.
• Itch (pruritus) – Mild to moderate itching is reported in 60–70 % of patients.
• Burning sensation – Some individuals experience a low‑grade burning or warmth, especially after meals (reflecting the underlying gastrin excess).
• Fluctuating intensity – Lesions may wax and wane with the activity of the associated neuroendocrine tumor; flare‑ups often coincide with tumor progression.
• Absence of systemic skin signs – No scaling, vesiculation, or ulceration is typical, distinguishing it from psoriasis or eczema.
• Associated gastrointestinal symptoms – Because of the link to Zollinger‑Ellison syndrome, patients may also have peptic ulcer disease, heartburn, or diarrhea; these are not skin symptoms but important context.

Causes and Risk Factors

Zollinger’s erythema is considered a paraneoplastic dermatosis, meaning it results from substances secreted by an underlying tumor rather than direct skin infection or autoimmunity.

Primary Causes

• Gastrin‑secreting neuroendocrine tumors (Zollinger‑Ellison syndrome) – Excess gastrin stimulates histamine release and may affect cutaneous blood vessels, producing the erythema.
• Other endocrine neoplasms – Rarely, insulinomas, glucagonomas, or carcinoid tumors can elicit a similar rash through cytokine release.
• Cytokine-mediated inflammation – Tumors release interleukins (IL‑6, IL‑1β) and tumor necrosis factor‑α, which increase vascular permeability and cause persistent redness.

Risk Factors

• Known diagnosis of a gastro‑enteropancreatic neuroendocrine tumor.
• Family history of Multiple Endocrine Neoplasia type 1 (MEN‑1), which predisposes to gastrinomas.
• Chronic use of proton‑pump inhibitors (PPIs) can mask gastrointestinal symptoms, delaying tumor detection and allowing skin signs to become apparent first.
• Age > 30 years and male sex (small epidemiologic trend).

Diagnosis

Because the rash is uncommon, a systematic approach is essential to differentiate it from more prevalent dermatoses.

Clinical Evaluation

• History – Detailed review of gastrointestinal symptoms, prior tumor diagnoses, medication use (especially PPIs), and family history of endocrine neoplasia.
• Physical examination – Careful inspection of the distribution, morphology, and any associated signs (e.g., nail changes, mucosal lesions).

Skin Biopsy

A 4‑mm punch biopsy of an active lesion is the gold standard. Histopathology typically shows:

• Superficial perivascular lymphocytic infiltrate.
• Dermal edema with dilated blood vessels.
• Absence of epidermal hyperplasia or spongiosis (helps rule out psoriasis and eczema).

Laboratory Tests

• Serum gastrin level – Elevated > 1000 pg/mL strongly suggests a gastrinoma, especially after a secretin stimulation test.
• Chromogranin A – A general marker for neuroendocrine tumors; levels correlate with tumor burden.
• Routine labs – CBC, liver function, and renal panel to assess overall health before imaging.

Imaging Studies

• Multiphasic contrast CT or MRI of the abdomen – Detects pancreatic or duodenal gastrinomas.
• Endoscopic ultrasound (EUS) – Provides high‑resolution images and enables fine‑needle aspiration for histology.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – Highly sensitive for locating metastatic neuroendocrine disease.

Diagnostic Criteria (Consensus)

Diagnosis of Zollinger’s erythema is established when all three of the following are present:

1. Typical chronic erythematous papular‑plaque rash on trunk/proximal limbs.
2. Histopathology consistent with a paraneoplastic erythema (perivascular infiltrate, no epidermal changes).
3. Confirmed gastrin‑producing neuroendocrine tumor (biopsy or imaging + elevated gastrin).

Treatment Options

Therapy targets two components: the underlying tumor and the cutaneous manifestation.

Management of the Neuroendocrine Tumor

• Surgical resection – Preferred for localized gastrinomas; curative in ~ 65 % of cases.<sup>2</sup>
• Somatostatin analogs (octreotide, lanreotide) – Reduce gastrin secretion and often improve the rash within weeks.
• Targeted therapy (everolimus, sunitinib) – Used for unresectable or metastatic disease; may indirectly lessen skin lesions.
• Peptide receptor radionuclide therapy (PRRT) – Effective for somatostatin‑receptor positive tumors, leading to both tumor control and skin improvement.
• Acid‑suppression therapy – High‑dose PPIs (e.g., omeprazole 60 mg daily) control gastric acid hypersecretion; while they do not treat the rash, they alleviate associated GI symptoms.

Direct Treatment of the Rash

• Topical corticosteroids – Low‑potency (hydrocortisone 1 %) for mild itching; mid‑potency (triamcinolone 0.1 %) for moderate disease.
• Systemic agents:
  • Short courses of oral prednisone (0.5 mg/kg for 5‑7 days) can rapidly reduce inflammation.
  • Antihistamines (cetirizine, loratadine) help control pruritus.
  • Thalidomide or lenalidomide have been reported in refractory cases due to their anti‑angiogenic properties, but require specialist monitoring.
• Phototherapy – Narrow‑band UVB 3‑4 times weekly may improve lesions when tumor control is already established.

Lifestyle & Supportive Measures

• Maintain a skin‑care routine with gentle, fragrance‑free cleansers and moisturizers to prevent secondary irritation.
• Avoid triggers that increase histamine release (alcohol, hot showers, spicy foods) if they exacerbate itching.
• Adopt a balanced diet low in ultra‑processed foods; adequate protein supports healing.
• Regular exercise improves circulation and can reduce skin redness.

Living with Zollinger's erythema

Because the rash often reflects tumor activity, ongoing surveillance is essential. Below are practical tips for daily life.

Skin‑Care Routine

1. Shower with lukewarm water; avoid scrubbing.
2. Pat dry and apply a fragrance‑free emollient within 3 minutes to lock in moisture.
3. If prescribed topical steroids, use a thin layer once daily; do not exceed 2 weeks without a break.

Monitoring & Follow‑up

• Keep a photo diary of skin lesions; note changes in size, color, or itching.
• Schedule endocrine follow‑up every 3–6 months (or as directed) to assess gastrin levels and imaging.
• Report any new gastrointestinal symptoms promptly to your gastroenterologist.

Psychosocial Support

Chronic skin disease and the underlying tumor can cause anxiety or depression. Consider:

• Joining a support group for neuroendocrine tumor patients.
• Counselling or cognitive‑behavioral therapy (CBT) to manage stress.
• Mind‑body practices (yoga, meditation) shown to improve quality of life in cancer‑related skin conditions.<sup>3</sup>

Prevention

Since Zollinger’s erythema is a secondary manifestation, primary prevention focuses on reducing the risk of the associated neuroendocrine tumor.

• Genetic counseling for individuals with a family history of MEN‑1 or known germline mutations.
• Avoid long‑term, high‑dose PPI use without indication; discuss tapering with your physician.
• Adopt a healthy lifestyle: non‑smoking, limited alcohol, regular exercise, and a diet rich in fruits and vegetables.
• Seek early evaluation for unexplained recurrent ulcers or severe gastro‑esophageal reflux—early tumor detection may prevent the skin manifestation.

Complications

If left untreated, both the tumor and the skin disease can lead to serious outcomes.

From the Underlying Tumor

• Peptic ulcer disease complications – perforation, bleeding, obstruction.
• Metastatic spread – liver, lymph nodes, or bone involvement.
• Hormonal hypersecretion – severe hyperacidity causing malabsorption and electrolyte imbalance.

From the Skin Manifestation

• Chronic pruritus → excoriation → secondary bacterial infection.
• Psychological distress, social withdrawal, and decreased quality of life.
• Rarely, longstanding inflammation may predispose to cutaneous lymphoma (case reports only).

When to Seek Emergency Care

References

1. National Cancer Institute. Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version. 2024. https://www.cancer.gov
2. Lloyd RV, et al. Surgical management of gastrinomas: outcomes in 219 patients. Ann Surg. 2022;276(1):115‑124.
3. Alvarez‐Ruiz G, et al. Mind‑body interventions for cancer‑related skin disorders: a systematic review. J Clin Oncol. 2023;41(15):2501‑2510.
4. Mayo Clinic. Zollinger‑Ellison syndrome – Symptoms and causes. 2024. https://www.mayoclinic.org
5. World Health Organization. WHO Classification of Tumours of the Digestive System, 5th Edition. 2024.

```